Homology Medicines Inc (NASDAQ:FIXX) COO Siyamak Rasty sold 8,000 shares of Homology Medicines stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $20.00, for a total transaction of $160,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Siyamak Rasty also recently made the following trade(s):
- On Monday, June 3rd, Siyamak Rasty sold 8,000 shares of Homology Medicines stock. The stock was sold at an average price of $20.22, for a total transaction of $161,760.00.
Shares of Homology Medicines stock opened at $19.51 on Friday. Homology Medicines Inc has a twelve month low of $15.07 and a twelve month high of $31.80. The business has a 50-day simple moving average of $19.37. The firm has a market cap of $839.57 million, a PE ratio of -9.76 and a beta of 0.16.
A number of institutional investors have recently modified their holdings of FIXX. RTW Investments LP raised its stake in Homology Medicines by 275.6% in the 4th quarter. RTW Investments LP now owns 1,633,491 shares of the company’s stock worth $36,525,000 after purchasing an additional 1,198,574 shares in the last quarter. BlackRock Inc. raised its stake in Homology Medicines by 134.3% in the 4th quarter. BlackRock Inc. now owns 1,460,449 shares of the company’s stock worth $32,656,000 after purchasing an additional 837,099 shares in the last quarter. Polar Capital LLP acquired a new stake in Homology Medicines in the 4th quarter worth about $2,236,000. Marshall Wace North America L.P. acquired a new stake in Homology Medicines in the 1st quarter worth about $2,582,000. Finally, Northern Trust Corp raised its stake in Homology Medicines by 49.6% in the 4th quarter. Northern Trust Corp now owns 181,361 shares of the company’s stock worth $4,055,000 after purchasing an additional 60,163 shares in the last quarter. Institutional investors and hedge funds own 52.87% of the company’s stock.
FIXX has been the subject of several research analyst reports. ValuEngine raised shares of Alleghany from a “hold” rating to a “buy” rating in a report on Friday, April 19th. Zacks Investment Research downgraded shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Evercore ISI initiated coverage on shares of Homology Medicines in a report on Thursday, April 11th. They set an “outperform” rating and a $29.00 target price for the company. Finally, HC Wainwright set a $4.00 target price on shares of Uranium Energy and gave the stock a “buy” rating in a report on Tuesday, June 11th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $29.10.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Recommended Story: What does the Dow Jones Industrial Average (DJIA) measure?
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.